Pharsight

1. List of Ponvory drug patents

Application	Filing Date	Opposition Party	Legal Status
EP15807916A	2022-10-26	STADA Arzneimittel AG	Granted and Under Opposition
EP15807916A	2022-10-21	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43728	JANSSEN PHARMS	Thiazolidin-4-one derivatives	Nov, 2024 (1 year, 5 months from now)
US9062014	JANSSEN PHARMS	Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one	May, 2032 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9000018	JANSSEN PHARMS	Thiazolidin-4-one-derivatives	Nov, 2024 (1 year, 5 months from now)
US8273779	JANSSEN PHARMS	Thiazolidin 4-one derivatives	Dec, 2025 (2 years from now)
US10220023	JANSSEN PHARMS	Dosing regimen for a selective S1P1 receptor agonist	Dec, 2035 (12 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 18, 2026

NCE-1 date: 2025-03-18

Market Authorisation Date: 18 March, 2021

Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2MG	TABLET;ORAL	Prescription
3MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
5MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription